S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
ACB   3.80 (+5.27%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
ACB   3.80 (+5.27%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

MYOS Stock Price, News & Analysis (NASDAQ:MYOS)

$1.44
-0.06 (-4.00 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
$1.44
Now: $1.44
$1.56
50-Day Range
$1.40
MA: $1.49
$1.59
52-Week Range
$1.04
Now: $1.44
$2.02
Volume778 shs
Average Volume5,571 shs
Market Capitalization$13.20 million
P/E RatioN/A
Dividend YieldN/A
Beta0.8
MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes. The company sells its Re Muscle Health products through e-commerce Website remusclehealth.com; and Qurr line of products through convenient direct online ordering without a prescription. MYOS RENS Technology Inc. has a research agreement with the University of California to study the effects Of Fortetropin on skeletal muscle protein synthetic rate in older men and women; and Rutgers University for the discovery development and commercialization of products that improve muscle health and performance. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MYOS
CUSIPN/A
Phone973-509-0444

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$360,000.00
Book Value$0.38 per share

Profitability

Net Income$-3,220,000.00
Net Margins-603.47%

Miscellaneous

Employees12
Market Cap$13.20 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive MYOS News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOS and its competitors with MarketBeat's FREE daily newsletter.


MYOS (NASDAQ:MYOS) Frequently Asked Questions

What is MYOS's stock symbol?

MYOS trades on the NASDAQ under the ticker symbol "MYOS."

How were MYOS's earnings last quarter?

MYOS Co. (NASDAQ:MYOS) posted its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The firm earned $0.15 million during the quarter, compared to analysts' expectations of $0.14 million. MYOS had a negative net margin of 603.47% and a negative return on equity of 93.90%. View MYOS's Earnings History.

When is MYOS's next earnings date?

MYOS is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for MYOS.

Has MYOS been receiving favorable news coverage?

Press coverage about MYOS stock has trended negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. MYOS earned a coverage optimism score of -2.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for MYOS.

Are investors shorting MYOS?

MYOS saw a drop in short interest during the month of September. As of September 15th, there was short interest totalling 75,000 shares, a drop of 10.9% from the August 15th total of 84,200 shares. Based on an average daily trading volume, of 11,900 shares, the days-to-cover ratio is presently 6.3 days. Approximately 1.5% of the shares of the stock are sold short. View MYOS's Current Options Chain.

Who are some of MYOS's key competitors?

What other stocks do shareholders of MYOS own?

Who are MYOS's key executives?

MYOS's management team includes the folowing people:
  • Mr. Joseph Mannello, CEO & Director (Age 61)
  • Mr. Ren Ren, Global Chairman (Age 57)
  • Mr. Joseph DiPietro, Controller
  • Mr. Magshoud Dariani, Chief Technology Officer
  • Mr. Kris Ohrenick, Head of Marketing

How do I buy shares of MYOS?

Shares of MYOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is MYOS's stock price today?

One share of MYOS stock can currently be purchased for approximately $1.44.

How big of a company is MYOS?

MYOS has a market capitalization of $13.20 million and generates $360,000.00 in revenue each year. The company earns $-3,220,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis. MYOS employs 12 workers across the globe.View Additional Information About MYOS.

What is MYOS's official website?

The official website for MYOS is http://www.myoscorp.com/.

How can I contact MYOS?

MYOS's mailing address is 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ, 07927. The company can be reached via phone at 973-509-0444 or via email at [email protected]


MarketBeat Community Rating for MYOS (NASDAQ MYOS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  188
MarketBeat's community ratings are surveys of what our community members think about MYOS and other stocks. Vote "Outperform" if you believe MYOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Featured Article: What are Bollinger Bands?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel